Patents by Inventor Kishore Kumar Konda
Kishore Kumar Konda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220125732Abstract: The invention relates to a solid, pharmaceutical composition in compressed tablet form. The tablet comprises an ibuprofen core tablet, a pair of protective barriers and a famotidine outermost coating. The ibuprofen core tablet comprises ibuprofen and one or more pharmaceutically acceptable excipients selected from disintegrants, diluents, fillers, binders, glidants and lubricants. The pair of protective barrier coatings surround the ibuprofen core tablet. The first coating comprises a methacrylic acid and ethyl acrylate copolymer, a surfactant, and hydroxypropylmethylcellulose. The second coating comprises hydroxypropylmethylcellulose, and a plasticizer. The outermost coating comprises famotidine, polyvinyl alcohol and a plasticizer.Type: ApplicationFiled: October 8, 2021Publication date: April 28, 2022Applicant: APPCO PHARMA LLCInventors: Peddanna Gumudavelli, Kishore Kumar Konda, Srinivasa R. Paruchuri, M.V.K. Satish, Y.V. Raghava Chowdary
-
Patent number: 11278502Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: GrantFiled: September 28, 2018Date of Patent: March 22, 2022Assignee: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
-
Patent number: 10786464Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: GrantFiled: November 3, 2010Date of Patent: September 29, 2020Assignee: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
-
Publication number: 20190192490Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: ApplicationFiled: November 26, 2018Publication date: June 27, 2019Applicant: Lupin Limited ( Research Park)Inventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Publication number: 20190029968Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: ApplicationFiled: September 28, 2018Publication date: January 31, 2019Applicant: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
-
Patent number: 10137114Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: GrantFiled: November 10, 2015Date of Patent: November 27, 2018Assignee: LUPIN LIMITEDInventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Publication number: 20160136141Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: ApplicationFiled: November 10, 2015Publication date: May 19, 2016Applicant: LUPIN LIMITEDInventors: Harshal Anil JAHAGIRDAR, Kishore Kumar KONDA, Satish Kumar DALAL, Shirishkumar KULKARNI
-
Patent number: 9211258Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: GrantFiled: March 9, 2011Date of Patent: December 15, 2015Assignee: LUPIN LIMITEDInventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Publication number: 20150209432Abstract: The present invention relates to pharmaceutical compositions of Proton Pump Inhibitor and process for preparation of such composition thereof. The invention relates to pharmaceutical compositions comprising Proton Pump Inhibitor, crospovidone, basic inorganic salt and one or more pharmaceutically acceptable excipients. The present invention provides stable pharmaceutical compositions of Dexlansoprazole which are bioequivalent to marketed dual delayed release pharmaceutical compositions of Dexlansoprazole.Type: ApplicationFiled: July 22, 2013Publication date: July 30, 2015Applicant: LUPIN LIMITEDInventors: Kishore Kumar Konda, Pandarinath Jadhav, Satish Kumar Dalal, Shirish Kumar Kulkarni
-
Publication number: 20130072512Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: ApplicationFiled: March 9, 2011Publication date: March 21, 2013Inventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Publication number: 20120219631Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: ApplicationFiled: November 3, 2010Publication date: August 30, 2012Applicant: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda